The short-term impact of Botox injections on speech disability in adductor spasmodic dysphonia

Disability and Rehabilitation

Volumn 19, Issue 1, 1997, Pages 20-25

  Epstein, Ruth ^a   Stygall, Jan ^b   Newman, Stanton ^b  

^a MIDDLESEX HOSPITAL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Adductor spasmodic dysphonia; Botox; Speech disability

Indexed keywords

BOTULINUM TOXIN A;

ADULT; AGED; ARTICLE; AVOIDANCE BEHAVIOR; CLINICAL ARTICLE; COMPREHENSION; DISABILITY; DYSPHONIA; FACTORIAL ANALYSIS; FEMALE; HUMAN; INTERPERSONAL COMMUNICATION; MALE; PRIORITY JOURNAL; QUESTIONNAIRE; SOCIAL ISOLATION; SPEECH REHABILITATION; SPEECH THERAPY; VOICE;

EID: 0031030105     PISSN: 09638288     EISSN: None     Source Type: Journal    
DOI: 10.3109/09638289709166441     Document Type: Article

References (31)

1. Bowling A. Measuring Disease. Buckingham, Philadelphia: Open University Press, 1995.
2. Hollister MG, Weintraub JA. The association of oral status with systemic health, quality of life, and economic production. Journal of Dental Education 1993; 57: 901-912.
3. Fitzsimmons B, Bunting LK. Quality of life of hemodialysis patients. Anna Journal 1993; 20: 575-582.
4. Haberman M, Bush N, Young K, Sullivan KM. Quality of life of adult long-term survivors of bone marrow transplantation: A qualitative analysis of narrative data. Oncology Nursing Forum 1993; 20: 1545-1553.
5. Tope DM, Ahles TA, Silberfarb PM. Psychological well being as one component of quality of life. Psychotherapy and Psychosomatics 1993; 60: 129-147.
6. Bendtsen P, Hornquist JO. Severity of rheumatoid arthritis, function and quality of life: subgroup comparisons. Clinical and Experimental Rheumatology 1993; 11: 495-502.
7. Juniper EF, Guyatt GH, William A, Griffith LA. Determining a minimal important change in a disease-specific quality of life questionnaire. Journal of Clinical Epidemiology 1994; 47: 81-87.
8. Lang C. HIV and quality of life; a rehabilitation perspective. Health Visitor 1993; 66: 445-446.
9. Aronson AE. Clinical Voice Disorders: an interdisciplinary approach. New York: Thieme-Stratton, 1980.
10. Colton RH, Casper JK. Understanding Voice Problems. San Francisco: Williams & Wilkins, 1990.
11. Arnold GE. Changing interpretations of a persistent affliction. Logos 1959; 2: 3-14.
12. Bloch P. Neuro-psychiatric aspects of spastic dysphonia. Folia Phoniatrica 1965; 17: 301-364.
13. Brodnitz F. Spastic dysphonia. Annals of Otorhinolaryngology 1976; 85: 210-214.
14. Blitzer A, Brin M, Fahn S, Lovelace R. Clinical and laboratory characteristics of laryngeal dystonia: A study of 110 cases. Laryngoscope 1988; 98: 636-640.
15. Cannito MP, Kondraske GV, Johns DF. Oral facial sensorimotor function in spasmodic dysphonia. In: Moore C, Yorkstone K & Benkelman D (eds) Dysarthria and Apraxia of Speech: Perspective on management. Baltimore: Paul H Brookes, 1991; 205-225.
16. Blitzer A, Brin M. Treatment of spasmodic dysphonia (laryngeal dystonia) with local injections of botulinum toxin. Journal of Voice 1992; 6: 365-369.
17. Ford CN, Bless DM, Patel NY. Botulinum toxin treatment of spasmodic dysphonia: techniques, indications, efficacy. Journal of Voice 1992; 6: 370-376.
18. Ludlow CL, Naunton RF. Sedory SE, Schultz MA, Hallett MD. Effects of botulinum toxin injections on speech in adductor spasmodic dysphonia. Neurology 1988; 38: 1220-1225.
19. Ludlow CL, Rhew K, Nash EA. Botulinum toxin injections for adductor spasmodic dysphonia. In: Jancovic J & Hallett M (eds) Therapy with Botulinum Toxin. New York: Marcel Dekker, 1994; 437-450.
20. Wade DT. Measurement in Neurological Rehabilitation. Oxford: Oxford University Press, 1992.
21. World Health Organisation's (WHO) International Classification of Impairment, Disability and Handicap (ICIDH). A Manual Classification Relating to Consequence of Disease. Geneva: WHO, 1980.
22. Smith MPH, Nichols S, Lemke J et al. Effects of voice disorders on patient lifestyle: preliminary results. NCVS Status and Progress Report 1993: 237-248.
23. Wilson DK. Voice Problems of Children, 3rd edn. Baltimore: Williams & Wilkins, 1987.
24. Zwirner P, Murry T, Swendon M, Woodson GE. Acoustic changes in spasmodic dysphonia after botulinum toxin injection. Journal of Voice 1991; 5: 78-84.
25. Aronson AE, McCaffery TV, Litchy WJ, Lipton RJ. Botulinum toxin injection for adductor spasmodic dysphonia: Patient self-ratings of voice and phonatory effort after three successive injections. Laryngoscope 1993; 103: 683-692.
26. Cannito MP, Murry T, Woodson GE. Attitudes toward communication in adductor spasmodic dysphonia before and after botulinum toxin injection. Journal of Medical Speech-Language Pathology 1994; 2: 125-133.
27. Smith MPH, Verdolini K, Gray S. et al. Effect of voice disorders on quality of life. NCVS Status and Progress Report, 1994: 1-17.
28. Oxenham D, Sheard C, Adams R. Comparison of clinician and spouse perceptions of the handicap of aphasia: everybody understands 'understanding'. Aphasiology 1995; 9: 477-493.
29. Zwirner P, Murry T, Woodson GE. Perceptual relationships in spasmodic dysphonia. Journal of Voice 1993; 7: 165-171.
30. Carr AJ, Thompson PW. Towards a measure of patient-perceived handicap in rheumatoid arthritis. British Journal of Rheumatology 1994; 33: 378-382.
31. Enderby P. Outcome measures in speech therapy: Impairment, disability, handicap and distress. Health Trends 1992; 24: 61-64.